

**Genesis Health System  
Administrative Policy**

---

Policy Title: **Enoxaparin Prophylaxis Dosing Adjustments Based on Weight**      Effective Date: 10/01/2022

Department: Pharmacy      Reviewed/Revised: 09/15/2022

Owner Title: Clinical Pharmacist      Review Cycle: Biennial

---

Owner Signature: \_\_\_\_\_ Page 1 of \_\_

[Owner Signature here (must be signed by owner prior to uploading into Policy Manager)]

---

**I. POLICY:**

- This Protocol is intended to be used by pharmacists for making dosage adjustments to enoxaparin for DVT prophylaxis based on weight. This does not include therapeutically-dosed anticoagulants. It will allow pharmacists to adjust DVT prophylaxis in the form of subcutaneous enoxaparin based on a patient's weight.

**II. APPLICABLE BUSINESS UNITS:**

All GHS Business Units:

- |  |   |
|--|---|
| <input type="checkbox"/> Crescent Laundry                                | <input checked="" type="checkbox"/> Genesis Medical Center, Aledo     |
| <input type="checkbox"/> Crosstown Square                                | <input checked="" type="checkbox"/> Genesis Medical Center, Davenport |
| <input type="checkbox"/> Genesis Accountable Care Organization           | <input checked="" type="checkbox"/> Genesis Medical Center, DeWitt    |
| <input type="checkbox"/> Genesis Convenient Care                         | <input checked="" type="checkbox"/> Genesis Medical Center, Silvis    |
| <input type="checkbox"/> Genesis EAP                                     | <input type="checkbox"/> Genesis Occupational Health                  |
| <input type="checkbox"/> Genesis Family Medical Center                   | <input type="checkbox"/> Genesis Philanthropy                         |
| <input type="checkbox"/> Genesis FirstMed Pharmacy                       | <input type="checkbox"/> Genesis Psychology Associates                |
| <input type="checkbox"/> Genesis Health Group                            | <input type="checkbox"/> Genesis VNA                                  |
| <input type="checkbox"/> Genesis Health Group, Aledo Rural Health Clinic | <input type="checkbox"/> Genesis Workplace Services                   |
| <input type="checkbox"/> Genesis Health Group, Erie Rural Health Clinic  | <input type="checkbox"/> Genesis Workers Comp Plan & Trust            |
| <input type="checkbox"/> Genesis Health Services Foundation              |   |
| <input type="checkbox"/> Genesis Home Medical Equipment                  |   |
| <input type="checkbox"/> Genesis Hospice                                 |   |

**III. APPLICABLE ORGANIZATIONAL ROLES:**

Pharmacists

**IV. PURPOSE:**

To standardize dosing of subcutaneous enoxaparin for DVT prophylaxis

**Genesis Health System  
Administrative Policy**

**V. DEFINITIONS:**

DVT Prophylaxis: Deep vein thrombosis prophylaxis  
SQ: subcutaneous

**VI. GENERAL CONSIDERATIONS:**

- Pharmacists will use actual body weight to adjust enoxaparin for DVT prophylaxis
- Weight cutoffs will be: < 50 kg, 50-120 kg, and > 120 kg
- Enoxaparin dose adjustments based on weight can be overridden by the practitioner writing “Dose Dispense as Written” in the comment field in Cerner

**VII. PRACTICE/PROCEDURE:**

**Enoxaparin**

Weight	Dose
< 50 kg	30 mg SQ daily
50-120 kg	40 mg SQ daily
> 120 kg	40 mg SQ bid

\*Higher doses (> 40 mg bid) for prophylaxis will not be decreased automatically by pharmacy

\*Provider may specify DAW in the order comments if desired

**VIII. REFERENCES:**

1. Rumbaugh K, Schmidt L. Venous Thromboembolism Prophylaxis Guidelines. Vanderbilt University Medical Center Multidisciplinary Surgical Critical Care. [https://www.vumc.org/trauma-and-scc/sites/vumc.org.trauma-and-scc/files/public\\_files/Manual/VTE%20Prophylaxis%20Guideline%20Update%20-%20Final%20Sept%202018.pdf](https://www.vumc.org/trauma-and-scc/sites/vumc.org.trauma-and-scc/files/public_files/Manual/VTE%20Prophylaxis%20Guideline%20Update%20-%20Final%20Sept%202018.pdf). Publication date unavailable. Updated October 2018. Accessed September 28, 2022.
2. Sebaaly J, Covert K. Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations. *Ann Pharmacother*. 2018;52(9):898-909. doi:10.1177/1060028018768449
3. Wang T-F, Milligan PE, Wong CA, Deal EN, Thoenke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. *Thrombosis and haemostasis*. 2014;111(1):88-93. doi:10.1160/TH13-01-0042.
4. Joy M, Tharp E, Hartman H, et al. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients. *Pharmacotherapy*. 2016;36(7):740-748. doi:10.1002/phar.1775
5. Beall J, Woodruff A, Hempel C, Wovkulich M, Zammit K. Efficacy and Safety of High-Dose Subcutaneous Unfractionated Heparin Prophylaxis for the Prevention of Venous Thromboembolism in Obese Hospitalized Patients. *Hospital pharmacy*. 2016;51(5):376-381. doi:10.1310/hpj5105-376

**IX. SUPERSEDES:**

**Genesis Health System  
Administrative Policy**

N/A

**X. CROSS REFERENCE:**

N/A

**XI. ENDORSEMENTS:**

GMC Pharmacy and Therapeutics Committee, 11/22